5-MeO-MiPT
| Clinical data | |
|---|---|
| Other names | 5-Methoxy-N-methyl-N-isopropyltryptamine; Moxy; Moxie; MSD-001; MSD001 |
| Routes of administration | Oral, smoking |
| Drug class | Non-selective serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen; Entactogen |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | Oral: 30 min (15–45 min) Oral, peak: 1–2 hours |
| Duration of action | Oral: 4–6 hours or 3–8 hours Smoked: 2–5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.223.426 |
| Chemical and physical data | |
| Formula | C15H22N2O |
| Molar mass | 246.354 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 100 to 244 °C (212 to 471 °F) (free base) 162 to 163 °C (324 to 325 °F) (hydrochloride) |
| |
| |
| (verify) | |
5-MeO-MiPT, also known as 5-methoxy-N-methyl-N-isopropyltryptamine or by its nickname Moxy, is an atypical psychedelic drug of the tryptamine and 5-methoxytryptamine families. It has unique and unusual effects compared to other psychedelic tryptamines. At low doses, its effects include stimulation, tactile and sexual enhancement, some MDMA-like entactogenic effects, and introspective and mild perceptual changes with few or no psychedelic visuals or time dilation, whereas at higher doses, it produces 5-MeO-DMT-like classical psychedelic effects. It is usually taken orally or smoked.
The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors, among others. It is closely related in chemical structure and effects to 5-MeO-DiPT, and is also related to other tryptamines like 5-MeO-DMT, 4-HO-MiPT, and MiPT.
5-MeO-MiPT was first described in the literature by Alexander Shulgin and David Repke and colleagues in 1985. It was later described by Shulgin in greater detail in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). Recreational use of 5-MeO-MiPT is significant but relatively rare. It is often used as a substitute for 5-MeO-DiPT, which has similar effects but was became a controlled substance in the United States in 2003. The Drug Enforcement Administration (DEA) proposed banning 5-MeO-MiPT as well in the 2020s, but later withdrew its proposal amid public opposition. 5-MeO-MiPT, under the developmental code name MSD-001, is being developed for the treatment of psychiatric disorders by Mindstate Design Labs and is in phase 1 clinical trials for this purpose as of 2025.